دورية أكاديمية

Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

التفاصيل البيبلوغرافية
العنوان: Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
المؤلفون: Zalcberg, John Raymond, Jones, Robin Lewis, Blay, Jean-Yves, George, Suzanne, Gelderblom, Hans, Schöffski, Patrick, von Mehren, Margaret, Kang, Yoon-Koo, Abdul Razak, Albiruni Ryan, Trent, Jonathan C., Attia, Steven, Le Cesne, Axel, Davis, Erika, Achour, Haroun, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Bauer, Sebastian, Heinrich, Michael C.
المصدر: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p748-748, 42p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2024.42.3_suppl.748